Center-Authored Papers

Filters: Author is Chen, Robert  [Clear All Filters]
2012
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S et al..  2012.  Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(18):2183-2189. Abstract
Chen R, Palmer JM, Thomas SH, Tsai N-C, Farol L, Nademanee A, Forman SJ, Gopal AK.  2012.  Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.. Blood. 119(26):6379-81. Abstract
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B et al..  2012.  Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(5):589-597. Abstract
2013
Han TH, Gopal AK, Ramchandren R, Goy A, Chen R, Matous JV, Cooper M, Grove LE, Alley SC, Lynch CM et al..  2013.  CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody-Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies.. Journal of clinical pharmacology. 53(8):866-77. Abstract
Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J et al..  2013.  Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Lymphomas: A Retrospective Evaluation of Safety and Efficacy.. Leukemia & lymphoma. Abstract
2014
Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD et al..  2014.  Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.. Journal of hematology & oncology. 7(1):24. Abstract
Illidge T, Bouabdallah R, Chen R, Gopal AK, Moskowitz CH, Ramchandren R, Shustov AR, Tilly H, Trippett TM, Gibb A et al..  2014.  Allogeneic Transplant Following Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma.. Leukemia & lymphoma. :1-34. Abstract
2015
Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, Bordoni RE, Friedberg JW, Sharman JP, Palanca-Wessels MC et al..  2015.  Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.. Blood. 126(26):2798-2804. Abstract
Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Chi X et al..  2015.  Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.. Blood. 125(8):1236-43. Abstract
Perales M-A, Ceberio I, Armand P, Burns LJ, Chen R, Cole PD, Evens AM, Laport GG, Moskowitz CH, Popat U et al..  2015.  Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(6):971-983. Abstract
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R et al..  2015.  Hodgkin lymphoma, version 2.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(5):554-86. Abstract
2016
Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D et al..  2016.  Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.. Blood. Abstract
2017
Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S et al..  2017.  Targeting BTK with ibrutinib in relapsed/refractory marginal zone lymphoma.. Blood. Abstract
Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart CA et al..  2017.  Academic Cancer Center Phase I Program Development.. The oncologist. Abstract
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA et al..  2017.  Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(5):608-638. Abstract